Enanta Pharmaceuticals Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    VKTX or ENTA: What to Expect from Revenue Growth in 2019

    Wall Street analysts have projected Enanta Pharmaceuticals’ revenues to be $220.13 million, $193.28 million, and $166.89 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///medications _
    Company & Industry Overviews

    What Are Analysts Recommending for VKTX and ENTA?

    Of the nine analysts covering Viking Therapeutics, three have rated the company as a “strong buy,” and six have rated it as a “buy.”

    By Margaret Patrick
  • uploads///NVR PE MC
    Consumer

    Analysing NVR, DPZ, ENTA And QLYS Stocks

    Growth stock analysis   NVR NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and […]

    By Amanda Lawrence
  • uploads///proj pe ratio
    Consumer

    Total Returns and Sector Exposure for Growth Indexes—Continued

    The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.

    By Amanda Lawrence
  • uploads///GROWTH INDEX EXPO TO IT
    Consumer

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).

    By Amanda Lawrence
  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April

    Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”

    By Kenneth Smith
  • uploads///ENTA
    Company & Industry Overviews

    Exploring Enanta Pharmaceuticals’ Product Pipeline

    Enanta Pharmaceuticals initiated a Phase 2 clinical study of EDP-305 in PBC patients in December 2017.

    By Kenneth Smith
  • uploads///ENTA
    Company & Industry Overviews

    A Look at Enanta Pharmaceuticals’ Financial Performance

    In 1Q18, Enanta Pharmaceuticals (ENTA) generated total revenues of $38.1 million compared with $10.4 million in 1Q17.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.